Cencora Appoints Eva Boratto as CFO, Reaffirms Fiscal 2026 Adjusted EPS Outlook

Cencora Inc. (COR) named Eva Boratto as executive vice president and chief financial officer on May 27, 2026, effective immediately. The drug distributor also reaffirmed its adjusted earnings-per-share guidance range for the fiscal year ending September 30, 2026. Boratto succeeds James Cleary, who held the CFO role since 2023. She brings experience from leadership roles at major pharmaceutical and healthcare companies. The transition occurs as Cencora continues to integrate recent acquisitions and manage pharmaceutical supply-chain dynamics. The company did not alter its profit forecast, signaling operational stability during the leadership change. Cencora had previously projected adjusted EPS for fiscal 2026 in a range that reflected mid-single-digit growth over the prior year. Shares of Cencora, which is headquartered in Conshohocken, Pennsylvania, fell 0.4% in midday trading following the announcement.